NORTHWEST BIOTHERAPEUTICS INCNWBO
| Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|
| Cash and cash equivalents | 18 | 13 | 22 | 6 | 0 | 22 | 0 | 10 | 15 | 7 | 2 | 2 |
|---|
| Prepaid expenses and other current assets | 0 | 0 | 1 | 1 | 1 | 2 | 3 | 6 | 2 | 2 | 2 | 2 |
|---|
| Total current assets | 19 | 15 | 24 | 8 | 1 | 24 | 3 | 16 | 17 | 9 | 4 | 4 |
|---|
| Property, plant and equipment, net | 0 | 40 | 46 | 0 | 0 | 0 | 0 | 1 | 15 | 13 | 17 | 16 |
|---|
| Right-of-use asset, net | - | - | - | - | - | - | 5 | 4 | 5 | 4 | 4 | 4 |
|---|
| Indefinite-lived intangible asset | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 |
|---|
| Goodwill | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 |
|---|
| Other assets | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
|---|
| Total non-current assets | 0 | 44 | 47 | 45 | 48 | 1 | 6 | 17 | 23 | 22 | 24 | 23 |
|---|
| TOTAL ASSETS | 19 | 58 | 71 | 53 | 49 | 25 | 9 | 33 | 40 | 31 | 28 | 27 |
|---|
| Accounts payable and accrued expenses | - | - | - | - | 13 | 16 | 6 | 7 | 7 | 11 | 10 | 17 |
|---|
| Accounts Payable And Accrued Liabilities Related Parties Current | - | - | - | - | 5 | 5 | 1 | 5 | 4 | 7 | 4 | 4 |
|---|
| Convertible notes, net | - | - | - | - | - | - | 1 | 4 | 0 | 0 | 4 | 2 |
|---|
| Convertible notes at fair value | - | - | - | - | - | - | - | - | - | - | 13 | 18 |
|---|
| Notes payable, net | - | 1 | 1 | - | 7 | 7 | 6 | 2 | 7 | 15 | 4 | 14 |
|---|
| Contingent payable derivative liability | - | - | - | - | - | - | 7 | 8 | 8 | 9 | 9 | 10 |
|---|
| Warrant liability | - | 45 | 28 | 5 | 40 | 30 | 20 | 355 | 107 | 81 | 1 | 2 |
|---|
| Investor advances | - | - | - | - | - | 0 | - | - | - | 3 | 0 | 0 |
|---|
| Share payable | - | - | - | - | - | - | - | - | - | 1 | 0 | 0 |
|---|
| Lease liabilities | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Total current liabilities | 20 | 69 | 65 | 76 | 88 | 70 | 41 | 382 | 134 | 126 | 45 | 68 |
|---|
| Convertible Notes At Fair Value, Non Current | - | - | - | - | - | - | - | - | - | - | - | 16 |
|---|
| Notes Payable, Noncurrent | - | - | - | 3 | 3 | 2 | 7 | 9 | 25 | 6 | 20 | 12 |
|---|
| Operating Lease, Liability, Noncurrent | - | - | - | - | - | - | 5 | 5 | 5 | 4 | 4 | 4 |
|---|
| Contingent payment obligation | - | - | - | - | - | - | - | - | - | - | 5 | 5 |
|---|
| Total non-current liabilities | - | 25 | 11 | 3 | 9 | 2 | 12 | 13 | 30 | 10 | 30 | 37 |
|---|
| Total liabilities | 20 | 93 | 75 | 79 | 96 | 72 | 53 | 396 | 164 | 136 | 75 | 106 |
|---|
| Series C Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | - | 16 |
|---|
| Temporary Equity, Carrying Amount, Attributable to Parent | 9 | - | - | - | - | - | - | - | - | 23 | 19 | - |
|---|
| Preferred Stock, Value, Issued | - | - | - | - | - | - | - | - | - | - | - | - |
|---|
| Common Stock, Value, Issued | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|---|
| Additional paid-in capital | 375 | 486 | 631 | 687 | 722 | 776 | 795 | 1,009 | 1,067 | 1,165 | 1,291 | 1,345 |
|---|
| Stock subscription receivable | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Accumulated deficit | - | - | - | - | - | -824 | -840 | -1,371 | -1,192 | -1,297 | -1,360 | -1,443 |
|---|
| Accumulated other comprehensive income | - | - | -0 | 2 | -1 | 1 | 1 | -1 | 0 | 3 | 2 | 3 |
|---|
| Total stockholders' deficit | - | - | - | - | - | - | - | - | - | 23 | 19 | - |
|---|
| TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT | 19 | 58 | 71 | 53 | 49 | 25 | 9 | 33 | 40 | 31 | 28 | 27 |
|---|